This work includes introducing next-generation sequencing and phenotypic testing in laboratories, ensuring the sustainable supply of drugs for drug-resistant tuberculosis, providing training, and strengthening disease surveillance techniques.
The implementation and monitoring of an innovative, six-month, all-oral regimen for the treatment of drug-resistant TB continued within the framework of the operational study led by the Republican Scientific and Practical Center of Pulmonology and Phthisiology (RSPC PP) in the capital, Minsk. Patients from across the country were enrolled in the study and began treatment during the year.
